| 1 |
34130909 | Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. | 2022 Jan |
1 |
| 2 |
34583027 | Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy. | 2022 Jan |
3 |
| 3 |
34688813 | CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. | 2022 Jan 30 |
7 |
| 4 |
34781138 | Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients. | 2022 Jan |
2 |
| 5 |
35389944 | Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. | 2022 Jul 1 |
7 |
| 6 |
35396676 | Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations. | 2022 Jun |
1 |
| 7 |
35562875 | Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. | 2022 Apr 19 |
3 |
| 8 |
35599203 | Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report. | 2022 May 19 |
1 |
| 9 |
32803289 | Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. | 2021 Jan |
2 |
| 10 |
32843687 | Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. | 2021 Feb |
3 |
| 11 |
32908236 | Correction: Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. | 2021 Feb |
1 |
| 12 |
32986876 | Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients. | 2021 Apr |
6 |
| 13 |
33278239 | High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. | 2021 Oct 1 |
1 |
| 14 |
33534527 | Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing. | 2021 Oct 1 |
1 |
| 15 |
33649515 | Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. | 2021 Jun |
2 |
| 16 |
33654003 | Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing. | 2021 Oct 1 |
2 |
| 17 |
34058078 | Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. | 2021 Sep |
1 |
| 18 |
34285488 | Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis. | 2021 |
2 |
| 19 |
34306041 | CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? | 2021 |
1 |
| 20 |
34620272 | Tacrolimus and herbs interactions: a review. | 2021 Oct 1 |
1 |
| 21 |
34725418 | CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. | 2021 Nov 1 |
6 |
| 22 |
31721244 | A novel random forest integrative approach based on endogenous CYP3A4 phenotype for predicting tacrolimus concentrations and dosages in Chinese renal transplant patients. | 2020 Apr |
6 |
| 23 |
31733802 | Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report. | 2020 Mar |
1 |
| 24 |
31955224 | Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients. | 2020 May |
1 |
| 25 |
32013193 | Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. | 2020 Jan 29 |
3 |
| 26 |
32308538 | Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. | 2020 |
1 |
| 27 |
32690569 | Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis. | 2020 Jul 20 |
2 |
| 28 |
32712713 | Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. | 2020 Dec |
1 |
| 29 |
32768638 | Co-administration of Wuzhi tablet (Schisandra sphenanthera extract) alters tacrolimus pharmacokinetics in a dose- and time-dependent manner in rats. | 2020 Dec 5 |
2 |
| 30 |
32848756 | The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. | 2020 |
3 |
| 31 |
32999170 | Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients. | 2020 |
1 |
| 32 |
33312896 | Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression. | 2020 Nov 28 |
1 |
| 33 |
33350247 | [An in vitro study on metabolic interaction between main active components of Salviae Miltiorrhizae Radix et Rhizoma and tacrolimus]. | 2020 Nov |
2 |
| 34 |
29479631 | Clinical aspects of tacrolimus use in paediatric renal transplant recipients. | 2019 Jan |
3 |
| 35 |
29989304 | In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. | 2019 Jan |
4 |
| 36 |
30058048 | Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice? | 2019 Jul |
4 |
| 37 |
30295407 | Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. | 2019 Feb |
1 |
| 38 |
30489455 | Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. | 2019 Jan |
2 |
| 39 |
30861159 | Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients. | 2019 Jun |
3 |
| 40 |
31045868 | Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. | 2019 Jun |
1 |
| 41 |
31061321 | Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule. | 2019 |
1 |
| 42 |
31152598 | Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers. | 2019 Dec |
1 |
| 43 |
31190414 | Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose. | 2019 Aug |
3 |
| 44 |
31244435 | Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients. | 2019 |
1 |
| 45 |
31261526 | Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients: An overview of systematic reviews. | 2019 Jun |
2 |
| 46 |
31401678 | CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria. | 2019 Nov |
1 |
| 47 |
31588879 | Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. | 2019 Oct |
3 |
| 48 |
31616470 | The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. | 2019 |
3 |
| 49 |
28945011 | Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. | 2018 Mar |
1 |
| 50 |
29160300 | Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. | 2018 May 22 |
3 |